baffr-car t cells
Cell therapyexperimental
Clinical trial activity
11 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 18, 2021 (NCT04690595)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lupus Erythematosus, Systemic · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Multiple Myeloma · Phase 1
- Myasthenia Gravis · Phase 1/Phase 2
- Myositis · Phase 1/Phase 2
- Neuromyelitis Optica · Phase 1/Phase 2
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Phase 1/Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- Tumor necrosis factor receptor superfamily member 13CImmunity, passive
immunity, passive - TNFRSF13C
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07259070 | Phase 1/Phase 2 (Phase 2) | Nov 29, 2025 | China Academy of Chinese Medical Sciences, Government of China |
| NCT07196111 | Early Phase 1 (Phase 1) | Oct 10, 2025 | Guangzhou Bio-gene Technology Co., Ltd. |
| NCT06916767 | Phase 1 | Jul 15, 2025 | Case Western Reserve University, The Leukemia and Lymphoma Society |
| NCT07022197 | Phase 1/Phase 2 (Phase 2) | Apr 10, 2025 | Tianjin Medical University |
| NCT06340750 | Phase 1 | Jan 15, 2025 | Luminary Therapeutics |
| NCT06561009 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2024 | Tianjin Medical University |
| NCT06191887 | Phase 1 | Mar 18, 2024 | Mayo Clinic |
| NCT05546723 | Phase 1 | Nov 1, 2022 | Case Western Reserve University, Luminary Therapeutics, The Cleveland Clinic |
| NCT05312801 | Phase 1 | Oct 2, 2022 | Case Western Reserve University, Luminary Therapeutics, University of Rochester |
| NCT05370430 | Phase 1 | Jun 13, 2022 | City of Hope National Medical Center, PeproMene Bio, Inc. |
| NCT04690595 | Phase 1 | May 18, 2021 | City of Hope National Medical Center, PeproMene Bio, Inc. |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Case Western Reserve University | Academic/Hospital | 3 | 1 | 1 | 2022 |
| Luminary Therapeutics | For profit | 3 | 3 | 1 | 2022 |
| City of Hope National Medical Center | Academic/Hospital | 2 | 0 | 1 | 2021 |
| PeproMene Bio, Inc. | For profit | 2 | 2 | 1 | 2021 |
| Tianjin Medical University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Government of China | Government | 1 | 0 | 1 | 2025 |
| Guangzhou Bio-gene Technology Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2024 |
| The Cleveland Clinic | Academic/Hospital | 1 | 0 | 1 | 2022 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2022 |
12 organizations
Page 1 / 1